topotecan
Also known as Hycamtin®, SK-S-104864-A, 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin, Topotecanum, 9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin, Topotecane
Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types.
Chemical data
- Formula
- C23H23N3O5
- Molecular weight
- 421.4 g/mol
- IUPAC name
- (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
- SMILES
- CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
- InChIKey
- UCFGDBYHRUNTLO-QHCPKHFHSA-N
- XLogP
- 0.5
- Polar surface area
- 103 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Research
3,947 papersArticle
9 sectionsContents
- Uses
- Experimental uses
- Angelman's syndrome
- Mechanism of action
- Side effects
- Generic versions
- References
- Sources
- External links
Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types.
After GlaxoSmithKline received final FDA approval for topotecan on 15 October 2007, it became the first topoisomerase I inhibitor for oral use.
Connections
Categories
Delta-lactonesDimethylamino compoundsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by GSK plcDrugs developed by NovartisDrugs with non-standard legal statusECHA InfoCard ID from WikidataLactamsMultiple chemicals in an infobox that need indexingMultiple chemicals in Infobox drug